Lanean...

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations

Trastuzumab is a recombinant humanized monoclonal antibody that selectively targets the extra-cellular domain of the HER2 receptor. It was approved by the FDA in September 1998 as the first targeted therapy for HER2-positive metastatic breast cancer, and has since led to significant improvements in...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Jeyakumar, Alwin, Younis, Tallal
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Libertas Academica 2012
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3327515/
https://ncbi.nlm.nih.gov/pubmed/22518088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.S6460
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!